Aurinia Pharmaceuticals Inc (AUPH)
7.18
-0.11
(-1.51%)
USD |
NASDAQ |
Oct 04, 16:00
7.18
0.00 (0.00%)
After-Hours: 16:32
Aurinia Pharmaceuticals Revenue (Quarterly): 41.49M for June 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 41.49M |
| March 31, 2023 | 34.41M |
| December 31, 2022 | 28.44M |
| September 30, 2022 | 55.78M |
| June 30, 2022 | 28.19M |
| March 31, 2022 | 21.62M |
| December 31, 2021 | 23.40M |
| September 30, 2021 | 14.67M |
| June 30, 2021 | 6.62M |
| March 31, 2021 | 0.914M |
| December 31, 2020 | 50.03M |
| September 30, 2020 | 0.029M |
| June 30, 2020 | 0.029M |
| March 31, 2020 | 0.03M |
| December 31, 2019 | 0.029M |
| September 30, 2019 | 0.23M |
| June 30, 2019 | 0.029M |
| March 31, 2019 | 0.03M |
| December 31, 2018 | 0.029M |
| September 30, 2018 | 0.375M |
| June 30, 2018 | 0.029M |
| March 31, 2018 | 0.03M |
| December 31, 2017 | 0.03M |
| September 30, 2017 | 0.029M |
| June 30, 2017 | 0.329M |
| Date | Value |
|---|---|
| March 31, 2017 | 0.03M |
| December 31, 2016 | 0.03M |
| September 30, 2016 | 0.031M |
| June 30, 2016 | 0.055M |
| March 31, 2016 | 0.057M |
| December 31, 2015 | 0.057M |
| September 30, 2015 | 0.057M |
| June 30, 2015 | 0.059M |
| March 31, 2015 | 0.062M |
| December 31, 2014 | 0.068M |
| September 30, 2014 | 0.072M |
| June 30, 2014 | 0.071M |
| March 31, 2014 | 0.067M |
| December 31, 2013 | 0.712M |
| September 30, 2013 | 0.084M |
| June 30, 2013 | 0.085M |
| March 31, 2013 | 0.088M |
| December 31, 2012 | 0.0862M |
| September 30, 2012 | 0.0874M |
| June 30, 2012 | 0.0885M |
| March 31, 2012 | 5.813M |
| December 31, 2011 | 0.12M |
| September 30, 2011 | 0.5348M |
| June 30, 2011 | 0.1528M |
| March 31, 2011 | 0.1379M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.029M
Minimum
Dec 2018
55.78M
Maximum
Sep 2022
16.11M
Average
6.62M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Acasti Pharma Inc | -- |
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.0932M |
| Liminal Biosciences Inc | 0.0833M |
| Xenon Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.49M |
| Total Expenses (Quarterly) | 57.66M |
| EPS Diluted (Quarterly) | -0.08 |
| Enterprise Value | 694.84M |
| Gross Profit Margin (Quarterly) | 96.23% |
| Profit Margin (Quarterly) | -27.70% |
| Earnings Yield | -6.96% |
| Normalized Earnings Yield | -6.964 |